Fostering an Interventional Glaucoma Culture

• by mdspire news news staff

• January 5, 2026

Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?

A large US cohort study found systemic alpha-2 agonist use was associated with a lower hazard of glaucoma-related diagnoses vs. beta-blockers.

• by Andrea Surnit

• July 8, 2026

• 3 min

Editorial: The role of light in myopia

• by Natali Gutierrez-Rodriguez, Valentina Bilbao-Malavé, Manuel Garza-León, Sandra Johana Ganzón-Parra, Jorge González-Zamora, Sergio Recalde Maestre

• September 2, 2026

Procedural Pharmaceutical Lessons From Early Adopters

Experienced glaucoma surgeons share practical pearls on integrating sustained drug delivery into practice.

• by Christine Funke, MD, J. Morgan Micheletti, MD, FACS, Jason Bacharach, MD, Shivani S. Kamat, MD, Arkadiy Yadgarov, MD, Steven R. Sarkisian, Jr., MD, Robert F. Melendez, MD, MBA, Syril K. Dorairaj, MD, and, Pranav Vasu, MPH, Savak “Sev” Teymoorian, MD, MBA, Reza Alizadeh, MD, Lorraine M. Provencher, MD, Jai G. Parekh, MD, MBA, FAAO, Manjool Shah, MD, Inder Paul Singh, MD, Huda Sheheitli, MD, Reena A. Garg, MD, Zarmeena Vendal, MD

• September 1, 2026

• 18 min